Compare Trump Media and Technology Group Corp (DJT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trump Media and Technology Group Corp vs Novartis AG — how do they compare? Trump Media and Technology Group Corp trades at $8.11 (market cap $2.28B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 117.8× Trump Media and Technology Group Corp's market cap, and Novartis AG pays a 3.31% dividend while Trump Media and Technology Group Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Trump Media and Technology Group Corp for 17 Days and Novartis AG for 82 Days on average.
| DJT | NVS | |
|---|---|---|
Market Cap | $2.28B | $268.57B |
Volume | 3,148,379 | 1,532,573 |
Sector | Media | Health |
52-Week High | $16.56 | $168.62 |
52-Week Low | $7.06 | $121.80 |
Typical Hold Time | 17 Days | 82 Days |
Enterprise Value | $2.35B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.20, down 0.24% with a bearish technical signal. The company reported $3.68M revenue for 2025 but a net loss of $712M, reflecting negative margins. Cash flow trends show heavy investing outflows partially funded by financing. Recent news highlights a proposed merger with TAE Technologies and insider selling activity.
Outlook remains challenged by persistent losses and high valuation multiples. The merger with TAE offers strategic diversification but execution risk is high. Investor sentiment is cautious amid weak fundamentals and negative profitability trends.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
